Skip Navigation Links   >   Home   >   News & Media
28 July 2020

OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

Oxford Cannabinoid Technologies (“OCT”), a UK-based biotechnology firm researching the potential of cannabinoids for treating a range of acute and chronic conditions, today announces the appointment of Dr Valentino Parravicini PhD as its new Chief Scientific Officer (“CSO”).  Dr Parravicini has joined the business to support the delivery of its objective to become a global leader in developing cannabinoid-based prescription medicine for indications in oncology, pain, immunology and neurology.

Dr Parravicini will oversee all of OCT’s ongoing drug discovery and development studies, including pre-clinical development of OCT461201, the company’s lead, highly selective and potent CB2 agonist, believed to be a potentially effective treatment for Irritable Bowel Syndrome (“IBS”) and other diseases. He will work closely with OCT’s lead business and research partners, while developing new research partnerships with other leading academic and commercial institutions around the world.

Dr Parravicini has a long and distinguished career in the fields of oncology, inflammation and immunology. He has led ground-breaking in vitro and in vivo projects and undertaken award-winning work in pharma and biotech focussed on small molecule and cell therapy approaches to autoimmunity and haematological malignancies. He is also an extensively published author on his discoveries and innovations with high-impact peer-reviewed publications in the fields of immunology and molecular virology.

Valentino Parravicini said: “I am delighted to be joining the team at Oxford Cannabinoid Technologies whose reputation precedes them. OCT’s search for transformative therapies to meet currently unmet medical needs is a perfect match with my past professional experience and my unquenchable desire to see how we can best harness cannabinoids to transform the lives of millions of people so that they live longer, more active lives.”

John Lucas, Chief Commercial Officer of OCT, said: “We are thrilled to have Valentino come on board. He has exactly the right kinds of skills sets that we need to help take OCT on the next stage of its exciting journey. This is a time of extraordinary and dynamic change and innovation in our sector and we are delighted to have him at our side to help us be that change and make it come alive for millions of sufferers around the world.”

    All News

    • Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address

      20 June 2022 Conference
    • OCT Investor Update 30 May 2022 - Q&A Questions

      30 May 2022 Investor Questions
    • The Cannabis Conversation: Cannabis Vs. Opioids with Valentino Parravicini

      18 May 2022 Podcast
    • Investor Meet Company Q&A Session

      16 May 2022 Investor Meet
    • Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy

      25 April 2022 Scientific Advisory Board
    • Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial

      31 March 2022 Programme Update
    • Data from pre-clinical study show positive results

      08 March 2022 Research Update
    • Requisition of General Meeting - Update

      04 March 2022 General Meeting
    • Requisition of General Meeting

      18 February 2022 General Meeting
    • Notice of Analyst and Investment Presentation - How to Register

      17 February 2022 Presentations
    • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

      18 November 2021 StemTech
    • Oxford Cannabinoid Technologies in drug development deal with Oxford StemTech

      17 November 2021 R&D Support
    • Posting of Annual Report, Notice of AGM and Form of Proxy

      27 October 2021 Annual Report, Notice of AGM and Form of Proxy
    • OCT Results and Company Update

      18 October 2021 Results and Company Update
    • Final Results and Notice of Annual General Meeting 13th October 2021

      13 October 2021 RNS
    • Oxford Cannabinoid Technologies work on treatment for chronic, painful disease Trigeminal Neuralgia

      12 October 2021 Trigeminal Neuralgia Interview
    • Oxford Cannabinoid Technologies Targets Chronic Pain Condition with Latest Formulation

      11 October 2021 Program 2 Announcement
    • OCT Explore the Opioid Crisis and Chronic Pain Pandemic in Pharmafocus Magazine

      30 September 2021 Pharmafocus Article
    • Good shape, good budget and on track for Oxford Cannabinoid Technologies Holdings

      28 September 2021 Podcast
    • Oxford Cannabinoid Technologies' deal for exclusive access to Canopy Growth's cannabinoid library

      22 September 2021 Canopy Growth
    • Oxford Cannabinoid Technologies says admission to the OTCQB is a logical next step

      02 September 2021 US Market
    • Oxford Cannabinoid Technologies announces strategic partnership with Evotec

      06 July 2021 Partnership
    • Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      Chief Scientific Officer Valentino Parravicini to speak at major cannabinoid-based drugs summit in Boston, Massachusetts

      24 June 2021 iCDP Speaker
    • Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      Meet the Team Interview Series: Dr John Lucas, Chief Executive Officer

      22 June 2021 Meet the Team Interview Series
    • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

      04 June 2021 Live Presentation
    • OCT Forges Partnership with Voisin Consulting Life Sciences

      OCT Forges Partnership with Voisin Consulting Life Sciences

      01 June 2021 OCT Partnership
    • Oxford Cannabinoid Technologies Announces Changes to Executive Team

      11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
    • OCT Company Values: How We Pursue Our Mission and Vision

      OCT Company Values: How We Pursue Our Mission and Vision

      01 December 2020 OCT Company Values
    • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

      Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

      26 October 2020 Meet the Team Interview Series
    • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

      07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
    • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

      OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

      28 July 2020 OCT Press Release
    • Cannabinoids in medicine part 5: Treating COVID-19

      17 June 2020 Open Access Government
    • Why the Government should continue to invest in Life Sciences post COVID-19

      Why the government should continue to invest in Life Sciences post COVID-19

      01 June 2020 OCT blog - John Lucas, COO
    • OCT researchers publish new study examining genes involved in treating neuropathic pain

      19 April 2020 OCT Press Release
    • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

      03 April 2020 OCT Press Release
    • Cannabinoids in medicine part 4: Epilepsy

      30 March 2020 Open Access Government
    • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

      07 January 2020 Open Access Government
    • Cannabinoids in medicine Part 2: Pain

      11 October 2019 Open Access Government
    • Cannabinoids in medicine Part 1: Cancer

      22 August 2019 Open Access Government
    • An interview with Neil Mahapatra

      08 January 2019 The Times Magazine
    • High life: the start-up hoping to unlock the secrets of medical cannabis

      09 August 2018 Evening Standard
    • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

      28 June 2018 OCT Press Release
    • Embracing the medical potential of cannabinoids

      01 June 2017 The Medicine Maker
    • Smashing the stigma with science

      01 June 2017 The Medicine Maker
    • Oxford University launches £10m research project into medical marijuana

      16 March 2017 Evening Standard
    • Oxford University to launch study on medical benefits of marijuana

      16 March 2017 The Telegraph
    • Oxford University to launch multimillion-dollar medical marijuana research program

      16 March 2017 CNBC
    • Oxford University launches £10m marijuana research programme

      16 March 2017 BBC
    • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

      15 March 2017 OCT Press Release